Investment

Company alerts >>

• September 26, 2022
  Recursion’s

  Recursion Pharmaceuticals

  Also known as: #N/A

  LT 2362

  362 of 560

  Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.

  Longevity pillar

  • Treatment
  • Prevention

  Longevity domain:

  • Discovery platforms

  Location: United States

  Year founded: 05-Nov-13

  Longevity target: Aging Disease, Aging Driver

  Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of September 27, 2022

  multi-year, strategic collaboration with Roche and Genentech.
• September 23, 2022
  Gameto

  Gameto

  Also known as: Gameto

  LT 2174

  174 of 560

  Gameto wants to synchronize the pace of ovarian aging to the rate of aging in other organs such as the liver, brain, or skin. When ovaries are termed “geriatric” by many traditional medical criteria, the rest of the body is certainly not and this creates conflict for people pushing them to make compromises they may not wish to make. Considering human healthspan and lifespan have increased significantly, Gameto believes this biological phenomenon is no longer fit for purpose and is a problem worth solving. The scientific work involves reconstituting ovarian development and function in vitro, elucidating the underlying growth factor and genetic networks that drive human ovarian development and oogenesis.

  Longevity pillar

  • Prevention
  • Renewal

  Longevity domain:

  • Reproductive longevity

  Location: United States

  Year founded: 01-Jan-20

  Longevity target: Aging Disease, Aging Driver

  Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of September 27, 2022

  is raising $26,999,944.00 in new equity investment.
• September 23, 2022
  BioChange

  BioChange ltd

  Also known as: #N/A

  LT 2059

  59 of 560

  BioChange has developed a breakthrough technology for tissue regeneration. A unique injectable scaffold that stimulates tissue repair and remodelling at the injected site. The scaffold is based on natural biomaterials designed for implantation using a minimally invasive procedure. It mimics the healthy Extra Cellular Matrix (ECM) and triggers the body to repair itself. Multiple long-term animal studies confirmed the safety and efficacy of the technology. The company is now selling products in the veterinary market and in tissue engineering research and is committed to start first clinical study in aesthetic dermatology in 2022.

  Longevity pillar

  • Renewal
  • Treatment

  Longevity domain:

  • Regeneration

  Location: Israel

  Year founded: 01-Jun-16

  Longevity target: Aging Disease

  Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of September 27, 2022

  develops a breakthrough technology for tissue regeneration to treat periodontitis.
• September 22, 2022
  Longevica

  Longevica

  Also known as: #N/A

  LT 2252

  252 of 560

  Longevica is a life science company researching the mechanisms of healthy aging and life extension. Longevica harnesses objective scientific research, clinical studies, research collaboration, and technology to develop novel, proactive therapeutic interventions to improve health and quality of life, prevent age-related disease, and facilitate the productive extension of lifespan.

  Longevity pillar

  • Prevention

  Longevity domain:

  • Repurposed Drugs
  • Discovery platforms

  Location: United States

  Year founded: 01-Jan-08

  Longevity target: Aging Driver

  Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of September 27, 2022

  raised $0.18mn in Later Stage VC funding.
• September 22, 2022
  Cumulus Neuroscience

  Cumulus Neuroscience

  Also known as: Cumulus

  LT 2118

  118 of 560

  Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform. In clinical trials it provides the critical data and insights needed to accelerate the delivery of more effective CNS drugs to patients.

  Longevity pillar

  • Treatment

  Longevity domain:

  • Discovery platforms
  • Neurotech

  Location: United Kingdom

  Year founded: 05-Jan-15

  Longevity target: Aging Disease

  Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of September 27, 2022

  appoints Aman Bhatti, MD as CEO.
• September 21, 2022
  Occuity

  Occuity

  Also known as: #N/A

  LT 2328

  328 of 560

  Occuity is developing solutions to some of humanity’s greatest health challenges through the invention of optical diagnostic technologies, to bring pain-free, non-contact screening & monitoring of chronic health conditions such as glaucoma, myopia, diabetes and Alzheimer’s Disease

  Longevity pillar

  • Diagnostic

  Longevity domain:

  • Longevity diagnostics

  Location: United Kingdom

  Year founded: 06-Sep-19

  Longevity target: Aging Disease

  Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of September 27, 2022

  secures Department for Trade funding.